Meeting
2012 ASCO Annual Meeting
64Cu-DOTA-trastuzumab-PET imaging in patients with HER2-positive breast cancer.
Authors
Kenji Tamura
Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
Kenji Tamura , Hiroaki Kurihara , Kan Yonemori , Kazuhiro Takahashi , Yasuhiro Wada , Koki Hasegawa , Fumiaki Koizumi , Hitoshi Tsuda , Makoto Kodaira , Mayu Yunokawa , Chikako Shimizu , Masashi Ando , Yasuyoshi Watanabe , Yasuhiro Fujiwara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Clinical Trial Registration Number
UMIN000004170
Citation
J Clin Oncol 30, 2012 (suppl; abstr 10519)
DOI
10.1200/jco.2012.30.15_suppl.10519
Abstract #
10519
Poster Bd #
12
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
![The HERPET study: Imaging HER2 expression in breast cancer with the novel PET tracer [<sup>18</sup>F]GE-226, a first-in-patient study.](https://d201v5jt9ylckg.cloudfront.net/288/14358/211270/211270_A4766_poster_pv.jpg)
The HERPET study: Imaging HER2 expression in breast cancer with the novel PET tracer [18F]GE-226, a first-in-patient study.
First Author: Laura M. Kenny
Poster
2022 ASCO Annual Meeting
Optimal timing and interval of imaging for metastatic breast cancer.
First Author: Shruti Rajesh Patel
Poster
2021 ASCO Annual Meeting
Imaging HER2-positive metastatic esophagogastric cancer with 89Zr-trastuzumab PET and 18F-FDG PET.
First Author: Melissa Amy Lumish
Poster
2016 ASCO Annual Meeting
Evaluation of tumor immune infiltrate as a determinant of response to neo-adjuvant lapatinib and trastuzumab (LT) in HER2-positive (+) breast cancer (BC).
First Author: Carmine De Angelis